STOCK TITAN

Innate Pharma to Participate in the 2025 Stifel Virtual Targeted Oncology Forum

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Innate Pharma (Nasdaq: IPHA) has announced its participation in the upcoming Stifel 2025 Virtual Targeted Oncology Forum, scheduled for April 8-9, 2025. The company's executive team will engage in two key activities during the event:

  • Host one-on-one meetings with stakeholders
  • Participate in a fireside chat on Wednesday, April 9, 2025, from 12:30 - 12:55 p.m. ET

The presentation will be accessible via live webcast and replay through the Events page in the Investors section of Innate Pharma's website.

Innate Pharma (Nasdaq: IPHA) ha annunciato la sua partecipazione al prossimo Stifel 2025 Virtual Targeted Oncology Forum, in programma per l'8 e il 9 aprile 2025. Il team esecutivo dell'azienda sarà coinvolto in due attività chiave durante l'evento:

  • Organizzare incontri individuali con gli stakeholder
  • Partecipare a una chiacchierata informale mercoledì 9 aprile 2025, dalle 12:30 alle 12:55 p.m. ET

La presentazione sarà accessibile tramite webcast dal vivo e in replica attraverso la pagina Eventi nella sezione Investitori del sito web di Innate Pharma.

Innate Pharma (Nasdaq: IPHA) ha anunciado su participación en el próximo Stifel 2025 Virtual Targeted Oncology Forum, programado para el 8 y 9 de abril de 2025. El equipo ejecutivo de la compañía participará en dos actividades clave durante el evento:

  • Organizar reuniones uno a uno con los interesados
  • Participar en una charla informal el miércoles 9 de abril de 2025, de 12:30 a 12:55 p.m. ET

La presentación estará disponible a través de una transmisión en vivo y una repetición en la página de Eventos en la sección de Inversores del sitio web de Innate Pharma.

Innate Pharma (Nasdaq: IPHA)는 2025년 4월 8일부터 9일까지 예정된 Stifel 2025 Virtual Targeted Oncology Forum에 참여한다고 발표했습니다. 회사의 경영진은 행사 동안 두 가지 주요 활동에 참여할 예정입니다:

  • 이해관계자와의 일대일 미팅 주최
  • 2025년 4월 9일 수요일, 오후 12:30부터 12:55까지 비공식 대화 참여

발표는 Innate Pharma 웹사이트의 투자자 섹션의 이벤트 페이지를 통해 실시간 웹캐스트 및 재생으로 접근할 수 있습니다.

Innate Pharma (Nasdaq: IPHA) a annoncé sa participation au prochain Stifel 2025 Virtual Targeted Oncology Forum, prévu pour les 8 et 9 avril 2025. L'équipe exécutive de l'entreprise participera à deux activités clés lors de l'événement :

  • Organiser des réunions individuelles avec les parties prenantes
  • Participer à une discussion informelle le mercredi 9 avril 2025, de 12h30 à 12h55 ET

La présentation sera accessible via un webinaire en direct et une rediffusion sur la page Événements de la section Investisseurs du site web d'Innate Pharma.

Innate Pharma (Nasdaq: IPHA) hat seine Teilnahme am bevorstehenden Stifel 2025 Virtual Targeted Oncology Forum angekündigt, das für den 8. und 9. April 2025 geplant ist. Das Führungsteam des Unternehmens wird während der Veranstaltung an zwei wichtigen Aktivitäten teilnehmen:

  • Einzelgespräche mit Stakeholdern veranstalten
  • An einem informellen Gespräch am Mittwoch, den 9. April 2025, von 12:30 bis 12:55 Uhr ET teilnehmen

Die Präsentation wird über einen Live-Webcast und eine Wiederholung über die Veranstaltungsseite im Investorenbereich der Innate Pharma-Website zugänglich sein.

Positive
  • None.
Negative
  • None.

MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News:

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that members of its executive team will present and host 1x1 meetings at the Stifel 2025 Virtual Targeted Oncology Forum being held on April 8 – 9, 2025.

The executive team will participate in a fireside chat scheduled on Wednesday, April 9, 2025, from 12:30 - 12:55 p.m. ET.

A live webcast and a replay of the presentation will be available on the Events page in the Investors section of Innate Pharma website.

About Innate Pharma

Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through three therapeutic approaches: multi-specific NK Cell Engagers via its ANKET® (Antibody-based NK cell Engager Therapeutics) proprietary platform and Antibody Drug Conjugates (ADC) and monoclonal antibodies (mAbs).

Innate’s portfolio includes several ANKET® drug candidates to address multiple tumor types as well as IPH4502, a differentiated ADC in development in solid tumors. In addition, anti-KIR3DL2 mAb lacutamab is developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, and anti-NKG2A mAb monalizumab is developed with AstraZeneca in non-small cell lung cancer.

Innate Pharma is a trusted partner to biopharmaceutical companies such as Sanofi and AstraZeneca, as well as leading research institutions, to accelerate innovation, research and development for the benefit of patients.

Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

Learn more about Innate Pharma at www.innate-pharma.com and follow us on LinkedIn and X.

Information about Innate Pharma shares

ISIN code
Ticker code
LEI

FR0010331421

Euronext: IPH Nasdaq: IPHA

9695002Y8420ZB8HJE29

Disclaimer on forward-looking information and risk factors

This press release contains certain forward-looking statements, including those within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. The use of certain words, including “anticipate,” “believe,” “can,” “could,” “estimate,” “expect,” “may,” “might,” “potential,” “expect” “should,” “will,” or the negative of these and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company’s reliance on third parties to manufacture its product candidates, the Company’s commercialization efforts and the Company’s continued ability to raise capital to fund its development. For an additional discussion of risks and uncertainties, which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority (“AMF”), which is available on the AMF website http://www.amf-france.org or on Innate Pharma’s website, and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 20-F for the year ended December 31, 2024, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company’s website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press release.

In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by the Company or any other person that the Company will achieve its objectives and plans in any specified time frame or at all. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

For additional information, please contact:

Investors

Innate Pharma

Henry Wheeler

Tel.: +33 (0)4 84 90 32 88

Henry.wheeler@innate-pharma.fr

Media Relations

NewCap

Arthur Rouillé

Tel.: +33 (0)1 44 71 00 15

innate@newcap.eu

Source: Innate Pharma SA

FAQ

When is Innate Pharma (IPHA) presenting at the Stifel 2025 Virtual Targeted Oncology Forum?

Innate Pharma will present on Wednesday, April 9, 2025, from 12:30 - 12:55 p.m. ET during a fireside chat session.

How can investors watch Innate Pharma's (IPHA) presentation at the Stifel 2025 Forum?

Investors can watch the presentation via live webcast or replay through the Events page in the Investors section of Innate Pharma's website.

What type of meetings will Innate Pharma (IPHA) host at the Stifel 2025 Oncology Forum?

Innate Pharma's executive team will host one-on-one (1x1) meetings with stakeholders during the forum.

What is the duration of the Stifel 2025 Virtual Targeted Oncology Forum where IPHA is presenting?

The Stifel 2025 Virtual Targeted Oncology Forum runs for two days, from April 8 to April 9, 2025.
Innate Pharma Sa

NASDAQ:IPHA

IPHA Rankings

IPHA Latest News

IPHA Stock Data

164.27M
83.83M
0.3%
0.55%
Biotechnology
Healthcare
Link
France
Marseille